---
layout: post
title: "Egis Pharmaceuticals Limited, et.al.; Proposal To Withdraw Approval of Three Abbreviated New Drug Applications; Opportunity for a Hearing"
date: 2026-02-04 21:37:14 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2025-23870
original_published: 2025-12-29 00:00:00 +0000
significance: 8.00
---

# Egis Pharmaceuticals Limited, et.al.; Proposal To Withdraw Approval of Three Abbreviated New Drug Applications; Opportunity for a Hearing

**Published:** February 04, 2026 21:37 UTC
**Source:** Federal Register
**Original Published:** December 29, 2025 00:00 UTC
**Document Number:** 2025-23870

## Summary

The Food and Drug Administration's (FDA or Agency) Center for Drug Evaluation and Research (CDER) is proposing to withdraw approval of three abbreviated new drug applications (ANDAs) and is announcing an opportunity for the ANDA holders to request a hearing on this proposal. The basis for the proposal is that these ANDA holders have repeatedly failed to file required annual reports for those ANDAs.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2025/12/29/2025-23870/egis-pharmaceuticals-limited-etal-proposal-to-withdraw-approval-of-three-abbreviated-new-drug)
- API: https://www.federalregister.gov/api/v1/documents/2025-23870

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
